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THE famous names of the lecturers who have given the Scott-Heron Lecture before
me, the weight of their subjects and the breadth of the areas of the world from which
they were drawn, ensure two things in any subsequent lecturer - a sense of awe and
a sense of apprehension. Both these sensations are mine, but I have had the temerity
to accept your wonderful invitation because they are subject to others - to the
honour you have done me, and my pleasure at it.
I have been told I can talk of a special interest in the clinical field, and I have
chosen systemic lupus erythematosus (S.L.E.). This condition is to me a fascinating
one. It used to be said that all medicine could be learnt from the study of syphilis,
and most acute medicine from patients with typhoid, and this is now very nearly
true for systemic lupus erythematosus. I do not pretend, of course, that systemic
lupus erythematosus is a common condition, but it is not a rare one, and as our
knowledge of its clinical manifestations has increased in the last 25 and even 10
years, so it is more frequently recognised. My personal records, and those of others,
lead me to believe that rheumatoid arthritis is about eight times commoner than
systemic lupus erythematosus, and that systemic lupus erythematosus is three times
commoner than scleroderma, polyarteritis nodosa or cranial arteritis, and six times
commoner than dermatomyositis. Although I have claimed that it has been recently
much better understood, I must admit that much of clinical interest was recognised
by our medical forebears before the turn of the last century and subsequently
largely forgotten.
Discussion of the nature of systemic lupus erythematosus has for some time
centred largely around the possibility of a disorder of immunity, and in particular
of auto-immunity, but the aetiology is still unknown. There are, however, other
factors upon which speculations can be based. The frequency with which this con-
dition affects women during the child-bearing period naturally suggests that the sex
hormones play an important part, but although the high mortality rate corresponds
suggestively to the levels of urinary oestrogen excretion, endocrine factors cannot
be the whole story as both men and women of all ages can be affected .
There is increasing evidence that genetic factors are of importance, both from
case histories showing a familial incidence, and from experimental observations, for
example, in the mice NZB (Burnet, 1965) and there are seven reports of S.L.E. in
identical twins, in one of which it was accompanied by multiple sclerosis in both
twins (Holmes et al., 1967). The report by Leonhardt (1967) is notable as he records
a family of 14 siblings, 3 of whom had S.L.E. associated with hypergammaglobu-
linaemia, a fourth had hypergammaglobulinaemia and 4 more had raised serum
globulin levels without any clinical manifestations.
The precipitating effect of certain drugs has some relevance here. Support for the
well established belief that hydralazine acts as a precipitant comes from a study of
fifty patients with the syndrome (Alarcon-Segovia et al., 1964) in which it was shown
that in 74 per cent. there were one or more findings to suggest that S.L.E. had pre-
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per cent. of the one hundred hypertensives who were given hydralazine without
developing the hydralazine syndrome. Family histories suggestive of S.L.E. were
also found in 34 per cent. of those with the syndrome, and in only 8 per cent. of
those who did not develop it. This evidence, and that from case histories like the
one described by Leonhardt, suggests that there may well be a pre-clinical genetically
determined state or diathesis for S.L.E. which can be precipitated into the active
disease by various factors such as drugs, and possibly infections. This conception
is not without its practical significance, indicating as it does the importance of
examining relatives of those with S.L.E. for auto-antibodies, or at any rate for
alteration in their plasma proteins. If any such abnormality is found, then extra
caution should be exercised when administering drugs to them, particularly if they
are women of child-bearing age. It is appreciated, as Bywaters (1967) pointed out,
that only a few out of the thousands of drugs used and in a very small proportion
of people who use them, is there any development of anit-nuclear factor (A.N.F.),
and once the drug is discontinued, both clinical manifestations and the A.N.F.
disappear. The presence of anti-nuclear antibodies does not necessarily provoke an
allergic disease, and normal antibody response to tissue damage and drugs is
evanescent. Still, such widely used drugs as antibiotics, sulphonamides, aneleptics,
anti-tuberculous preparations, thiouracils, phenylbutazone and procainamide have
been implicated in producing or precipitating lupus-like symptoms, and the abnor-
mality in patients with S.L.E. may be that in them the production of auto-antibodies
is not evanescent but persistent (Lachmann, 1967)
ANTINUCLEAR ANTIBODIES
Whatever the role of auto-immunity may be in this condition, the serum of
patients with S.L.E. contains non-organ-specific auto-antibodies, and their demon-
stration has proved of diagnostic value. These auto-antibodies can be considered in
two groups:
(i) Those which react with nuclear material, including deoxyribonucleic acid
(D.N.A.).
(ii) Those which react with cytoplasmic factors such as mitochondria and
microsomes, or with other tissues such as white cells and platelets.
It is generally agreed that the tests which are based on the presence in the serum
of antinuclear material are at present the most useful in practice. The best known
of these is of course the demonstration of the lupus erythematosus cell (L.E. cell)
by Hargraves. These cells are found in about 80 per cent. of patients when the
usual method is used, but with an improved one they have been found in 93 per
cent. of patients with S.L.E. (Arterberry et al., 1964). They are also found in
patients with so-called lupoid hepatitis, chronic parenchymatous hepatitis (cirrhosis)
and in rheumatoid arthritis. Tests for antinuclear factor (A.N.F.) in the serum are
sometimes used for screening, but can be positive when L.E. cells cannot be found
and negative in their presence.
MODE OF ONSET
The mode of onset of S.L.E. varies enormously, and it can mimic a large variety
of conditions.
An acute onset - An acute onset, with fever, wasting and often with skin lesions,
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three years. The diagnosis will quickly be established if L.E. cells are found early
on in the illness, but this is far from being invariably the case, and patients are
seen in whom they are only found once, and then in small numbers, or even in
whom they are never found although widespread histological changes are present
at autopsy.
Fever occurs in almost 100 per cent. of patients with an acute onset, and in 85
per cent. of all cases. Skin lesions are seen in about 70 per cent. of patients who
are acutely ill, and in half of all patients at the onset. Arthralgia may be a present-
ing feature in these patients (20 per cent.), but is more commonly seen when the
onset is insidious (75 per cent.). Acute renal lesions may occur at the onset, and
when they do they usually carry with them a bad prognosis. Blood disorders, such
as thrombocytopenic purpura or an acute acquired haemolytic anaemia, are some-
times early features of an acute onset.
A computer analysis of 520 patients by Dubois (1964) has shown that certain
combinations of clinical features are commonly observed. Arthralgia, fever, nephro-
pathy and anaemia were present in 30 per cent. of this large series, and arthralgia,
fever, adenopathy and pleurisy in 29.6 per cent. S.L.E. may, however, present in a
score of ways, and an interesting manner is when recurrent incidents of, for example,
pleurisy, pericarditis, mental symptoms and fits, precede the establishment of true
diagnosis.
Fever - Fever at the onset may be insignificant relative to the other symptoms and
the degree of illness of the patient. It may, on the other hand, be the sole feature,
when it may be high swinging, or sustained, the patient presenting as a problem in
diagnosis. Recurrent febrile periods accompany activity of the disease process, and
often mirror its degree, but at times patients are seen who are surprisingly free from
other symptoms, or even feel reasonably well with a persistent fever of about 101°.
SKIN LESIONS IN SYSTEMIC LuPus ERYTHEMATOSUS
The skin lesions of lupus erythematosus, including the chronic discoid type, are
common when compared with the rarer disorder of systemic lupus erythematosus.
They are chiefly confined to the head, including the face, scalp, lips and mucous
membranes. They are precipitated by exposure to sunlight and by cold. They may
leave unsightly scars from atrophy of the skin and telangiectasia, but not infre-
quently there is little or no residual disfigurement.
When systemic lupus erythematosus is present the skin may be unaffected or only
minimally so, with patchy erythema on the extremities, notably the backs of the
fingers and toes, but also on the trunk. The rash may, however, be very extensive,
involving in particular a butterfly area over the nose and cheeks, areas much exposed
to sunlight. Apart from the erythema, from which the disorder takes part of its
name, purpura can occur with or without thrombocytopenia. Swellings of the ex-
tremities, with colour and temperature changes and sometimes leg ulcers, which
can in some instances be due to cryoglobulinaemia (Larson, 1961) are not infrequent
features.
ARTHRITIS AND ARTHRALGIA
I have already stressed the high incidence of joint pains during the course of the
disease. The pains may be severe in some patients even when there are few accom-
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the source of pain, but other joints can also be affected.
Joint changes may resemble in appearance those of rheumatoid arthritis, and
sometimes there is an overlap between systemic lupus erythematosus and rheumatoid
arthritis. The joints may, however, have somewhat negative features; they are not
always symmetrically involved and the degree of destruction seen radiologically can
be less than might have been expected from the severity of the symptoms. The
muscles round them waste, not only from disuse but also from a polymyositis, which
is a feature of the condition.
SUBCUTANEOUS NODULES
These may occur on the extensor surfaces, closely resembling those of rheumatoid
arthritis clinically and histologically, with central necrosis and palisade of cells, or
rarely the nodules may be due to relapsing nodular non-suppurative panniculitis
without subsequent atrophy.
THE CARDIOVASCULAR SYSTEM
Peripheral vessels - Peripheral vascular lesions are commonly seen in patients
with discoid and with systemic lupus erythematosus, and Raynaud's phenomenon
can pre-date other symptoms by many years. Hutchinson's pernio, also known as
lupus pernio or chilblain lupus, is a classical manifestation. The patients may have
had chilblains for many years, usually with Raynaud-like colour changes, and their
fingers may be scarred by healed recurrent ulceration. Again, cryoproteins and
cryoprecipitation may be demonstrated.
Venous thromboses can occur at the onset as well as during the course of the
disease. They can be recurring or migratory, and thus systemic lupus erythematosus
should be considered as a possible cause of unexplained thrombosis and of throm-
bophlebitis migrans. The great vessels from the heart are occasionally involved in
an arteritis in systemic lupus erythematosus, thus mimicking Takayasu arteriopathy,
which in its turn can, at its onset, be mistaken for systemic lupus erythematosus.
The heart - A pericardial rub, to fibrinous pericarditis, is heard in about half of
the patients at one time or another. Pericarditis with effusion is rarer, but is never-
theless the commonest cause of an enlarged cardiac outline on the X-ray film in
this condition.
The disease process can involve the heart muscle, with consequent rhythm
changes, including auricular fibrillation and heart block. E.C.G. changes are there-
fore common (Brigden et al., 1960). Such a patient, a woman of 47, was recently
seen with cardiomegaly, congestive cardiac failure and an unexplained pyrexia, who
worried us a lot diagnostically until a large number of L.E. cells was found in her
blood. The response to steroids was dramatic, the high temperature fell at once and
the cardiac size returned to normal.
The classical evidence of cardiac involvement is of the valves, which was described
by Libman and Sacks as sterile verrucose endocarditis. The finding of heart mur-
murs resulting from valvular lesions is as important in differential diagnosis as in the
natural history of the patient's illness, as it raises the possibility of the presence of
sub-acute bacterial endocarditis, a condition that can mimic or accompany S.L.E.
Hypertension, with or without renal involvement, can of course lead to cardiac
enlargement.
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Transitory albuminuria, with an increase in the cellular deposit, is as commonly
found in S.L.E. as in any febrile condition. The prognosis is, however, adversely
affected in most cases to a very considerable degree when proteinuria persists, and
a renal lesion becomes established. Of eight such patients I have studied in detail,
three were dead within three years from the time of diagnosis, but two survived for
eight and nine years. Three were still alive after ten, four and two years, respectively,
but the last-mentioned was developing the signs of malignant hypertension, and had
a blood urea of 102 mgm. per cent. Thus of the eight, only three are known, or are
likely to have survived longer than five years from the time of diagnosis.
Gary and her associates (1967) have followed up eight patients with systemic
lupus erythematosus with established renal lesions of more than thirty months
duration. Four were initially in the nephrotic stage and two were azotaemic. All had
the renal lesions of systemic lupus erythematosus proven by renal biopsy, and
evaluated by strict criteria, such as the presence of haematoxylin bodies, and of
widening and granularity of the glomerular capillary walls. This group of patients
was observed to survive for periods ranging from 33 to 135 months without any
evidence of progression of their renal lesions.
The policy with regard to steroid therapy adopted by Gary was to give sufficiently
large doses of Prednisone to suppress the condition in the acute stages, and then to
keep the dosage at the minimal level necessary to maintain the patient's renal
function in an unprogressive state. This is a sensible approach provided one is pre-
pared to err on the side of the high dosage rather than low dosage.
It seems that although the prognosis is much worse in those patients who are
azotaemic or nephrotic, it is possible to survive with established renal lesions for a
considerable period. A study by Comerford (1967) of the histology of the kidney in
systemic lupus erythematosus, both by light and electron microscopy, has shown
that there can be definite histological involvement without any clinical evidence of
renal disease. He concluded:
(a) "There is considerable evidence that such injurious processes are related to
primary abnormalities within the circulation, and that these, at least in part,
are secondary to immune phenomena."
(b) "It is probable that an important secondary mechanism of renal injury is
related to intravascular coagulation, leading to the deposition of fibrinogen-
derived substances within the glomerulus, and the subsequent development of
chronic renal damage and disease."
LUNGS AND PLEURA
The pleura, like the pericardium, is frequently involved in systemic lupus erythe-
matosus, and recurring incidents of pleurisy should suggest the possibility that this
is the underlying condition. The pleural space may become obliterated, and when
an effusion is present L.E. cells may be found in the fluid. The commonest source of
involvement of the lungs is, of course, bacterial, with bronchitis or pneumonia, as in
any debilitating condition.
The radiological appearances of the lung fields are variable and have no special
characteristics; miliary mottling may be seen, or there may be ill-defined infiltra-
tions.
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with either an acute or a prolonged clinical course, can occur with systemic lupus
erythematosus. Both conditions have non-organ-specific auto-antibodies in the blood,
but the titre for A.N.F. is low and L.E. cells are absent in primary interstitial pul-
monary fibrosis, suggesting that they are separate conditions.
When the lungs are involved in patients with S.L.E. the lesions may not be solely,
or even partially due to this process, and the presence of a fungal infection must be
sought with the greatest care when steroids are being used. The commonest fungus
is Candida albicans, which can be respiratory or generalised, or occur at the site of
any local infection, or in the gastro-intestinal or renal tracts. In a recent report
(Pillay, 1968) the death of four patients was attributed to it, and it was considered
to have contributed to the demise of eight others. In addition to candidiasis, asper-
gillosis, nocardiosis and coccidioidomycosis can complicate systemic lupus erythe-
matosus, as of course can infection with Cryptococcus neoformans and the tubercle
bacillus. The importance of keeping a watchful eye open for these infections is
obvious.
THE LIVER
There are several very important but unanswered questions concerning the liver
and systemic lupus erythematosus. The liver is palpably enlarged in about a quarter
of the patients, and it is histologically involved in a higher proportion. Clinical
evidence of liver failure is nevertheless uncommon in patients with systemic lupus
erythematosus.
L.E. cells are present in a variety of liver disorders without there being any
evidence of systemic lupus erythematosus. They are found in some patients with
virus hepatitis (hepatic lupus), and in a few with cirrhosis (lupoid hepatitis), where
the prognosis is thought by some (MacKay and Wood, 1962) to be worse than in
certain other types of chronic liver disease, such as alcoholic cirrhosis. The presence
of L.E. cells in these various types of liver disease indicates an auto-immune process,
but one which is in all probability secondary to tissue damage rather than of primary
significance. Many authorities now consider that so-called lupoid hepatitis is essen-
tially hepatitis with abnormal serological reactions rather than a part of systemic
lupus erythematosus.
NEUROLOGICAL LESIONS
Some neurological involvement in systemic lupus erythematosus is common, and
authorities (Johnson and Richardson, 1968) have recently put the figure as high as
75 per cent. for involvement of the central nervous system, and at 8 per cent. for
peripheral nerve involvement. Although lesions in the central nervous system account
for a large number of deaths from this condition, just as in the case of renal lesions
their presence does not invariably imply a bad prognosis. Their origin is usually
from micro-infarcts in the cerebral cortex and brain-stem, and the serious clinical
manifestations, in order of frequency, are convulsions, disturbance of mental
function and signs referrable to the cranial nerves, but a wide variety of other
central nervous system signs and symptoms may occur, including disorders of move-
ment and of hypothalamic function (Honda, 1966).
Involvement of the peripheral nervous system may take the form of a mono-
neuritis multiplex, thus imitating a carcinomatous neuropathy or polyarteritis
nodosa, or the Guillain-Barre syndrome. The mononeuropathies are due to vascular
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immunology rather than structural changes in the vessel walls.
The effectiveness or otherwise of steroids on these neurological manifestations is
difficult to determine because they may recover spontaneously without any treatment
at all. When convulsions or severe mental disturbances are present the therapeutic
dilemma may be extremely taxing. It is of course well known that steroids can pro-
mote mental disorders, and indeed convulsions. On the other hand, schizophrenic
reactions undoubtedly occur unrelated to the use of steroids, and there are several
reports which claim therapeutic benefit from steroids in both affective and schizo-
phrenic incidents. From examining case histories it seems clear that some people
become psychotic shortly after the initiation of steroid therapy, and are relieved
when the dosage is reduced or the treatment stopped, only to relapse when the
previous dosage is restored. Others are relieved, or appear to be, by steroid therapy,
and yet others recover without any.
The situation is even more anxious when the patient is experiencing a series of
convulsions, or has developed status epilepticus. I personally find this a most diffi-
cult problem in the individual case, but my bias is towards increasing the dose of
steroids unless they have been very recently instituted, in a patient previously free
from all convulsions, on the grounds that if the fits are due to the decrease process,
the patient's best hope is in suppressing it, whereas, if the fits are due to steroids,
their mistaken continuation for a short time is the lesser of the two evils. Although
aneleptic drugs will of course be used in most instances, it is important and rather
frightening to remember that patients have developed systemic lupus erythematosus
whilst receiving Hydantoin or Primodone for epilepsy.
PREGNANCY AND SYSTEMIC LuPus ERYTHEMATOSUS
Acute systemic lupus erythematosus in pregnancy carries a high maternal mor-
tality rate which, as a result of a review of reported cases (Turner et al., 1955) is
put at between 20 and 60 per cent. for the mother, and 30 and 50 per cent. for the
foetus. When systemic lupus erythematosus in the mother is sub-acute, she usually
survives, but the foetal mortality is still high - about 40 per cent. Patients with dis-
coid lupus erythematosus and no generalisation have not been observed to have any
ill effects as a result of pregnancy.
The L.E. factor can pass the placental barrier and tests for it can remain positive
for several weeks, or even two to three months in the child. Although there is vir-
tually no risk to the child from this, it is obviously wise for a careful watch to be
kept on the haematologic state of a child born of a mother with active systemic
lupus erythematosus.
It has been suggested that women with systemic lupus erythematosus tend to have
a reduced fertility, but Larson's figures (1961) do little to support this. He found
that in the 62 patients of his who were of child-bearing age, there were 38 preg-
nancies. The present writer's experience has, however, been different, in that out of
31 women of child-bearing age recently studied, there were only 3 pregnancies. Two
of these had abortions about the fifth month, and in both the systemic lupus
erythematosus was exacerbated, in one with fatal results, whilst the other, who had
had the disease for five years before her pregnancy but had previously only suffered
from arthralgia, is now disfigured by her skin condition and disabled by arthritis.
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month, was delivered of a normal child, and has had no further symptoms. The
child also has remained well. Blood from the umbilical cord showed antinuclear
factor (A.N.F.) and L.E. cells, but neither were present some months later.
Only three of the 22 patients reported by Larson who had systemic lupus erythe-
matosus before becoming pregnant were definitely worse during their pregnancy, but
five had acute exacerbations shortly after delivery, and two women had an acute
onset of the condition in the second trimester. None of the children who were born
(22 out of 38 pregnancies) were abnormal, but there were 10 abortions and 6 still-
births. It seems that there is a real risk to the mother during pregnancy if systemic
lupus erythematosus is active, and that there is a high incidence of abortion or mis-
carriages once the disease is disseminated (Richardson, 1963).
PROGNOSIS
The discoid type of lupus erythematosus may remain ungeneralised and benign
indefinitely, although the skin lesions themselves persist in about half of the patients.
They can, nevertheless, disappear with little or no residual change. Generalisation,
however, occurs in about 10 per cent. of patients (Ingram, 1960), and may alter the
whole course of the illness, and with it the prognosis.
Systemic lupus erythematosus is a dangerous disease and even when the course is
benign, it rarely disappears entirely, although occasional examples are on record.
Dubois (1956) found the mean duration of the illness in patients untreated by
steroids was two years, and 80 per cent. of Hill's (1957) patients were dead in five
years. In series in which the follow up has been prolonged, more encouraging figures
have been recorded. Rupe and Nickel (1959) found that half of their patients were
alive at the end of 10 years, and Richardson (1965) one-third of his. One of Rupe
and Nickel's patients was alive 34 years from the onset, and two of Richardson's
over 25 years.
The type of onset affects the prognosis, and those with an acute onset have a
worse prognosis than those in whom it is insidious. The subsequent course of the
disease may be relatively benign with a good prognosis in respect of survival. One-
third are alive after 10 years from the onset, and have little serious disability; 66
per cent. of the surviving patients find life, at the worst, tolerable, and half of my
series regard themselves as well.
A more malignant course with a bad prognosis in respect of life and disability
must be feared under certain circumstances. The prognosis is particularly bad in
women during the reproductive period of their lives. It is often, like all other diseases
of the connective tissue, severely worsened by renal involvement. This however, is
not invariably the case, but the earlier a renal lesion occurs in the course of the
illness, the worse is its prognostic significance. Widespread arteritis or involvement
of the blood-forming organs, with consequent haemolytic reactions, neutropenia or
thrombocytopenia, are usually sinister, but both thrombocytopenia with purpura
and a haemolytic anaemia can be present for years before a fatal outcome super-
venes, or indeed evidence of systemic lupus erythernatosus develops.
TREATMENT
There is no specific treatment for systemic lupus erythematosus, but corticosteroids
undoubtedly have a very large place in the management of these patients. When an
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normal in the majority of instances within 48 hours. Pains in joints and muscles
reduce and the general sense of illness diminishes. Skin lesions, serious effusions,
glandular and organ enlargements are slower to improve, and the response may be
only partial. If anaemia, due to haemolysis, is present, it is soon brought under
control and the Coombs' test becomes negative .The number of L.E. cells in the
blood is reduced, the E.S.R. diminishes, as does the raised level of the gamma
globulins, and the biological false positive W.R. becomes negative.
The immediate outlook for the patient is largely determined by the initial response
to full doses of steroids, while the long-term prognosis depends greatly on the ability
to control the activity of the disease with small doses, i.e., about 15 mgm. of Predni-
sone, daily, or less. Pollak and his colleagues (1961) have succeeded in doubling
the life span of their patients with a renal lesion with high as compared to low
dosage of steroids, but only in those patients whose blood urea was less than 30
mgm. per 100 ml. when the renal lesion was first proved by renal biopsy. If, on the
other hand, the lesion is advanced, little benefit can be expected from steroids.
Corticotrophin (A.C.T.H.) is sometimes more effective than are corticosteroids.
It can be used in acute exacerbations by adding 20 to 40 units to an intravenous
drip of 5 per cent. glucose solution. It can also be given by intramuscular injection
in doses of 20 units of zinc corticotrophin twice in twenty-four hours. Corticosteroids
are sometimes used in combination with salicylates, and this may lead to the control
of symptoms with a lower dosage of steroids. Antimalarial preparations are added to
steroids on occasions, but there is little evidence that they have any additional
therapeutic effect. They can also be used alone. Chloroquin is usually given in divided
dosage, with a total of 150-300 mgm. of base daily. It has a good effect on the rash
of lupus erythematosus, but much less on the generalised manifestations. Its mode
of action is unknown, but its toxic effects are well recognised. They include nausea,
vomiting and headache, bleaching of the hair, and important ocular complications.
Transitory difficulty in accommodation and corneal opacities tend to disappear when
the drug is withdrawn, but a retinopathy somewhat resembling retinitis pigmentosa
may persist.
Valuable as steroids and A.C.T.H. undoubtedly can be in the management of
patients with systemic lupus erythematosus, they in no sense provide a complete
therapeutic answer, and thus other measures are always being sought.
Antimetabolites are undergoing appraisal at the present time. The theory is that
if antibody is produced by actively growing lines of lymphocytes which are especially
vulnerable to the action of purine antagonists, these drugs might have an immuno-
suppressive effect. Although their mode of action is not fully understood, 6-thio-
guanine (6-T.G.), 6-mercaptoprine (6-M.P.) or one of its derivatives azathioprine,
partially block the production of humoral circulatory antibodies, and, unlike corti-
sone, have some effect on delayed or cellular type of hypersensitivity (Corley et al.,
1966). Such clinical benefits as have occurred have been mostly in patients with
renal lesions, but in some instances the rashes, fever and arthralgia of systemic lupus
erythematosus have been improved even when steroids were not being given in com-
bination with the antimetabolite.
The dosage is critical, since if more than a purely temporary result is to be
achieved, enough must be given to threaten some degree of marrow depression. It
165may be between 1.25 mgm. to 2.5 mgm. per kilo per day, but must be determined
for each individual patient and be controlled by frequent blood counts. The actual
preparation chosen will depend upon the physician's experience, but azothioprine
has been shown to be considerably more immuno-suppressive in animals and man
than its parent substance 6-mercaptoprine (Steiner and Nabrady, 1965). The pos-
sibility that the combination of prednisone with an azothioprine preparation may
allow the later to be effective in non-toxic doses is being explored.
Before concluding, two points by way of prophylaxic must be made.
Patients with systemic lupus erythematosus are often extremely sensitive to drugs,
and great caution must be exercised in their use in these people. No drug whatso-
ever, and this includes immunising agents, should be given without very careful
thought.
Finally, these patients are sun-sensitive, and should be instructed to use an
efficient barrier cream, even if exposure to the sun is expected to be for only a
matter of minutes. Homely advice, but a good note on which to end.
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